November 12, 2021 04:40 AM ESTUpdated 07:17 AM
Peer Review

Cy­toIm­mune CEO breaks down her 3 'pil­lars' of suc­cess; For­mer No­var­tis, Gilead ex­ec Alessan­dro Ri­va to lead an ul­tra low-pro­file cell ther­a­py out­fit

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Paul Schloesser

Associate Editor

Christi­na Cough­lin loves cell ther­a­py — pret­ty much defin­ing her ca­reer since her post­doc days with Carl June in Penn­syl­va­nia.

Now as the new head hon­cho …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times